Sep 2026· Journal of Controlled Release· pp.
115372
· 0 citations
Medicine
TL;DR
In vivo studies of both anti-PD-L1-responsive and resistant tumor models demonstrated that intratumoral delivery of bPEI-Thy/siPD-L1 NCs substantially reduced tumor growth and metastatic spread, induced apoptosis, alleviated immunosuppression, and extended survival.
Abstract
Cancer continues to pose a major global health burden. Although immunotherapy has reshaped treatment strategies, its therapeutic effect is frequently limited by a suppressive tumor microenvironment and systemic toxicity. The stimulator of interferon genes (STING) pathway has emerged as a key target for coordinating innate and adaptive immunity through type I interferon signaling, yet insufficient activation and tumor-intrinsic resistance often constrain its benefit. Herein, we present an innovative branched polyethyleneimine (bPEI)-based nanodelivery platform designed to address these challenges by integrating STING activation with PD-L1 checkpoint blockade. The core of this platform is a novel thymine-functionalized bPEI polymer (bPEI-Thy), which acts as a polyvalent STING agonist and concurrently encapsulates PD-L1 siRNA into well-defined nanocomplexes (named as bPEI-Thy/siPD-L1 NCs, 65.76 nm, PDI 0.193, zeta potential 17.4 mV). In vitro, the NCs were internalized, facilitated endosomal escape, activated STING signaling, and reduced PD-L1 expression. In vivo studies of both anti-PD-L1-responsive and resistant tumor models demonstrated that intratumoral delivery of bPEI-Thy/siPD-L1 NCs substantially reduced tumor growth and metastatic spread, induced apoptosis, alleviated immunosuppression, and extended survival. Mechanistic evaluation showed enhanced dendritic cell maturation, activation of CD4+ and CD8+ T cells together with natural killer cells, an increased M1/M2 macrophage ratio, and reduced Treg infiltration. Notably, unilateral injection also suppressed tumor growth at distant sites, indicating systemic immune activation. Overall, these dual-functional bPEI-Thy/siPD-L1 NCs provide an integrated platform that activates innate immune pathways and blocks adaptive immune checkpoint blockade, offering a safe and effective strategy for synergistic cancer immunotherapy.
Activation of the stimulator of interferon genes (STING) pathway represents a promising strategy for cancer immunotherapy. However, clinical translation of STING agonists has been hampered by inefficient intracellular delivery and compensatory upregulation of the negative feedback immune checkpoint molecule of programm...
W. You, Fan Gao, Hai-Li Wang et al.· Bioactive Materials· 0 citations
A chemotherapy-induced supramolecular integrated co-delivery platform that simultaneously counteracts metastasis and immunosuppression via "drug-and-gene" therapy is established, offering a promising strategy for the treatment of aggressive cancer.
Jia-Yi Men, Xue-Yan Zhang, Wen-Jie Zhang et al.· Journal of Controlled Releas...· 0 citations
ABSTRACT STING agonists (e.g., cGAMP), which function as immunotherapeutic agents activating the stimulator of interferon genes (STING) pathway, hold promise for treating pediatric solid tumors including neuroblastoma. However, their clinical translation is hindered by limitations including burst release, short half‐li...
Yu-Bin He, Xiao Lu, Chang-Qing Yang et al.· Advancement of science· 0 citations
Stimulator of interferon genes (STING) agonists have shown limited antitumor efficacy, in part because STING activation is not preferentially focused on dendritic cells (DCs), which specialize in cross-priming. We present a DC-centric strategy that synergistically licenses DCs by coordinating CD47-SIRPα checkpoint reli...
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by the absence of targetable receptors and limited therapeutic options. Its inherently low immunogenicity necessitates strategies to enhance its susceptibility to immune attack. This study aimed to enhance the antitumor immune res...
D. Onan, Melike Özder, Gülşah Erel-Akbaba et al.· Molecular Pharmaceutics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.